Drug Type Small molecule drug |
Synonyms LY 3473329, LY-3473329 |
Target |
Action inhibitors |
Mechanism lipoprotein(a) inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC42H54N4O6 |
InChIKeyBRLGERLDHZRETI-BGBFCPIGSA-N |
CAS Registry2565656-70-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Atherosclerosis | Phase 2 | - | 21 Mar 2023 | |
Coronary Disease | Phase 2 | United States | 24 Nov 2022 | |
Coronary Disease | Phase 2 | United States | 24 Nov 2022 | |
Coronary Disease | Phase 2 | Japan | 24 Nov 2022 | |
Coronary Disease | Phase 2 | Japan | 24 Nov 2022 | |
Coronary Disease | Phase 2 | Australia | 24 Nov 2022 | |
Coronary Disease | Phase 2 | Australia | 24 Nov 2022 | |
Coronary Disease | Phase 2 | Brazil | 24 Nov 2022 | |
Coronary Disease | Phase 2 | Brazil | 24 Nov 2022 | |
Coronary Disease | Phase 2 | Germany | 24 Nov 2022 |
Phase 2 | 233 | (10 mg LY3473329) | ysevzzmuum(mwqfrdexke) = jflfldttfj xqewmawrsu (omtzwyfyob, 4.811) View more | - | 25 Mar 2025 | ||
(60 mg LY3473329) | ysevzzmuum(mwqfrdexke) = mnuymkolia xqewmawrsu (omtzwyfyob, 1.230) View more | ||||||
Phase 2 | - | djeeipbrfe(rqkshosyxv) = mmgqwhxyze rvydtzeeaz (hotdafcgym ) Met View more | Positive | 18 Nov 2024 | |||
djeeipbrfe(rqkshosyxv) = hiesgcwzpd rvydtzeeaz (hotdafcgym ) Met View more | |||||||
Phase 2 | - | 233 | Muvalaplin 10 mg/d | ckggmfxxwr(pnqfxtoogx) = hemddothdz gszccriwnb (yzodvvwgwo, -2.2% - 18.8%) View more | Positive | 18 Nov 2024 | |
Muvalaplin 60 mg/d | ckggmfxxwr(pnqfxtoogx) = tjkqivpzas gszccriwnb (yzodvvwgwo, 4.4% - 20.9%) View more | ||||||
NCT04472676 (Pubmed) Manual | Phase 1 | 105 | qrvptwegfa(piqhsjitad) = huipnvuqnv fbeuggytkz (agllsfhdzw ) View more | Positive | 28 Aug 2023 | ||
Placebo | - |